

ForPatients

by Roche

Non Hodgkin Lymphoma (NHL) Follicular Lymphoma B-cell Non-Hodgkin Lymphoma

A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Chemotherapy in Participants With Non-Hodgkin Lymphomas

Trial Status
Completed

Trial Runs In
9 Countries

Trial Identifier
NCT03467373 2017-003648-18
NP40126

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a phase 1B, multi-center, dose-finding study of glofitamab administered in combination with obinutuzumab (Gazyva; [G]), rituximab (R) and standard doses of CHOP (G/R-CHOP or R-CHOP) in participants with r/r NHL and G/R CHOP or Pola-R-CHP in participants with untreated diffuse large B-cell lymphoma (DLBCL). Evaluating the safety, preliminary activity, pharmacokinetic (PK), and pharmacodynamic effects of this combination will be the main objectives of this study. The study is divided in two parts: * Part I: Dose finding in participants with r/r NHL; test use of G vs R in Cycle 1 * Part II: Dose Expansion. The maximum tolerated dose or optimal biological dose (MTD or OBD) will be further assessed in participants with untreated DLBCL (>18 years of age with an age-adjusted International Prognostic Index (IPI) of 2-5). Glofitamab will be studied in combination with R-CHOP and Pola-R-CHP.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT03467373 2017-003648-18 NP40126
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years

Healthy Volunteers
No
